Publications
119
Citations
2,246
Est. group size
~26
Recurring co-author estimate
Active years
24
Publishing since 2003
Carlos Malvestutto's research focuses on cardiovascular disease risk and prevention in people living with HIV, largely through work connected to the large REPRIEVE clinical trial, which studies whether a cholesterol-lowering drug (pitavastatin) can reduce heart disease risk in this population. His work also touches on COVID-19 clinical outcomes, including long COVID and antiviral treatments. Much of the research combines clinical trial data with biomarkers (such as inflammation and aging markers) to better understand and predict cardiovascular events in HIV patients.
Publication output has grown substantially over the last decade, rising from just 1-2 papers per year in 2017-2019 to over 20 per year in 2023 and 2025, indicating a strongly increasing and currently high level of research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis
The Lancet HIV · 2026
- Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE
The Lancet HIV · 2026
- Association of long COVID with health-related quality-of-life outcomes
Scientific Reports · 2026
- Association of long COVID with health-related quality-of-life outcomes
UNC Libraries · 2026
- Inflammatory, Cardiac, and Lipid-Related Biomarkers in Relation to Residual MACE Risk in the REPRIEVE Trial
JACC Advances · 2026
- Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE
The Lancet HIV · 2025
- Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
Open Forum Infectious Diseases · 2025
- Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial
Clinical Infectious Diseases · 2025
- Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE Substudy
JACC Advances · 2025
- Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis
The Lancet HIV · 2025
- Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV
Journal of Clinical Investigation · 2025
- Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
Clinical Infectious Diseases · 2025
- Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Circulation Heart Failure · 2025
- Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial
Arteriosclerosis Thrombosis and Vascular Biology · 2025
- Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial
The Lancet HIV · 2025
- Open Forum Infectious Diseases×20
- Clinical Infectious Diseases×9
- The Lancet HIV×7
- AIDS×6
- JACC Advances×5
- Samir K. Gupta
Medicine · Indiana University
- Jean-Guy Baril
Medicine · Indiana University
- Susan L. Koletar
Medicine · The Ohio State University
- B Peters
Medicine · Purdue University West Lafayette
- Nicholas Funderburg
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile